TauroLock™-HEP100

• oncology
• parenteral nutrition
• intensive care 

• 1.35 % taurolidine: broad antimicrobial activity against bacteria and fungi without generating resistance
• 4 % citrate: anticoagulant to maintain patency
• 100 IU/ml heparin: anticoagulant to maintain patency 

• prevention of biofilm
• prevention of occlusion
• prevention of infection

• single dose: 3 ml ampoules (10 per box)
• store between 15 and 30 °C (do not freeze)
  

Longitudinal study 2020

“Our results support … the use of [TauroLock™-HEP100] in patients who have recurrent infections.” 

Leiberman et al. Clin Nutr ESPEN 2020. DOI: 10.1016/j.clnesp.2020.03.025 

Clinical study 2017

“In patients with intestinal failure who are life dependent on HPS [home parenteral support], [TauroLock™-HEP100] demonstrates a clinically substantial and cost-beneficial reduction of CRBSI [catheter-related bloodstream infection] occurrence in a high-risk population compared with heparin.”  

Tribler et al. Am J Clin Nutr 2017. DOI: 10.3945/ajcn.117.158964 

Clinical study 2013

“Locking of long-term tunneled CVC [central-venous catheters] with [TauroLock™-HEP100] significantly reduces catheter-related bloodstream infections in children with cancer.” 

Handrup et al. Pediatr Blood Cancer 2013 DOI: 10.1002/pbc.24482